Nutex Health, Inc.
NASDAQ:NUTXMedical - Healthcare Information Services
+$2.84 today
- Market cap
- $1.19B
- Beta
- 2.06
- P/E (TTM)
- 10.4
- EPS (TTM)
- $14.38
Volume 0.16M
Average 0.17M
NUTX Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Nutex Health, Inc.NASDAQ: NUTX
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures growth accelerates
Q1 FY2026 capital expenditures of $1.2M (cash outflow) rose 1776.6% year over year, ahead of the +124.1% change in trailing-twelve-month capital expenditures. Sequentially, it fell 14.8% from the prior quarter. Over 3 fiscal years it compounded at -44.3% a year.
Context
- Capital expenditures amounted to 0.3% of revenue in FY2025, down 0.2 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +1776.6% holds above the trailing-twelve-month pace of +124.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (2.53M) USD
- Year-over-year change
- -9.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.53M) | -9.6% |
| FY2024 | 2024-12-31 | (2.3M) | +75.7% |
| FY2023 | 2023-12-31 | (9.5M) | +35.1% |
| FY2022 | 2022-12-31 | (14.63M) | +60.4% |
| FY2021 | 2021-12-31 | (36.93M) | — |
Capital Expenditures vs competitors
How NUTX compares with its peers on the latest reported figures
- NUTX's LTM Mar 2026 capital expenditures of $3.66M is the smallest of the 11 companies compared; the peer median is $146.09M.
- Its year-over-year change of +124.1% is the highest of 11, against a peer median of +6.4%.
- Capital expenditures amounts to 0.4% of revenue for NUTX, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $992M | +10.0% | +9.8% | 4.5% | |
| LTM Jun 2026 | $973.58M | -2.5% | +11.4% | 5.4% | |
| LTM Jun 2026 | $799.1M | +19.9% | +8.0% | 12.9% | |
| LTM Mar 2026 | $326M | -7.4% | -6.9% | 1.5% | |
ARDTArdent Health Partners, LLC | LTM Mar 2026 | $217.08M | +16.4% | +11.9% | 3.4% |
| LTM Sep 2026 | $75.1M | -14.9% | -0.8% | 2.2% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $69.39M | -12.0% | +21.4% | 3.0% |
| LTM Mar 2026 | $26.56M | +41.9% | -26.0% | 0.5% | |
| LTM Mar 2026 | $11.39M | +16.8% | -45.3% | 1.2% | |
| LTM Mar 2026 | $11.04M | +2.8% | -23.9% | 0.3% | |
| LTM Mar 2026 | $3.66M | +124.1% | -44.3% | 0.4% | |
| Peer median (excluding NUTX) | $146.09M | +6.4% | +3.6% | 2.6% | |
Competitors are the stored peer set for NUTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 168.53M | (432.74M) | (43.42M) | 95.27M | 180.36M |
| Depreciation & Amortization | 7.66M | 13.13M | 17.59M | 18.97M | 20.53M |
| Deferred Income Tax | 0 | 5M | (5.71M) | (13.13M) | 17.08M |
| Stock-Based Compensation | 0 | 189.58K | 2.84M | 16.63M | 117M |
| Change in Working Capital | 2.75M | 64.32M | (1.66M) | (104.4M) | (87.74M) |
| Accounts Receivables | (6.62M) | 58.08M | (4.58M) | (173.41M) | (89.32M) |
| Inventory | (1.09M) | (719.11K) | 142.7K | 540.77K | (16K) |
| Accounts Payables | 6.27M | 9.69M | (2.25M) | (10.72M) | 37.85M |
| Other Working Capital | 4.2M | (2.73M) | 5.03M | 79.19M | (36.26M) |
| Other Non-Cash Items | (5.51M) | 400.71M | 31.62M | 9.81M | 902K |
| Operating Cash Flow | 173.43M | 50.61M | 1.26M | 23.15M | 248.13M |
| Capital Expenditures | (36.93M) | (14.63M) | (9.5M) | (2.3M) | (2.53M) |
| Acquisitions (Net) | (48.85K) | 10.3M | (1.74M) | (361.33K) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 1.6M |
| Other Investing Activities | 0 | 0 | 0 | 0 | (4.31M) |
| Investing Cash Flow | (36.98M) | (4.34M) | (11.24M) | (2.67M) | (5.24M) |
| Debt Repayment | (3.22M) | (5.59M) | 2.65M | (7.4M) | (19.44M) |
| Common Stock Issued | 0 | 4.76M | 0 | 9.2M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (5M) |
| Dividends Paid | (144.34M) | (51.23M) | (5.21M) | (6.44M) | (74.28M) |
| Other Financing Activities | 21.71M | 3.93M | 298.03K | 5.73M | 767K |
| Financing Cash Flow | (125.85M) | (48.13M) | (2.27M) | 1.09M | (97.95M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 10.6M | (1.86M) | (12.25M) | 21.58M | 144.93M |
| Free Cash Flow | 136.51M | 35.97M | (8.24M) | 20.85M | 245.6M |
Nutex Health, Inc.
NASDAQ:NUTX
Intrinsic Alpha fair value
Locked
Current Price
$172.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.